Calithera reports Phase I data for CB-839 combo in solid tumors

Calithera Biosciences Inc. (NASDAQ:CALA) reported data from 16 evaluable patients with advanced solid tumors in the Phase I portion of a Phase I/II trial showing that twice-daily 400-800 mg doses of oral CB-839 plus Xeloda capecitabine led to 10 cases of stable disease and a median progression-free survival (PFS) of 16.5 weeks. Nine of the 10 patients were resistant to fluoropyrimidine. In six patients with phosphoinositide 3-kinase (PI3K) catalytic subunit alpha polypeptide (PI3KCA; p110alpha) mutant colorectal cancer, CB-839 plus Xeloda led to a median PFS of 29.5 weeks.

The data were released in an abstract ahead of the American Society of Clinical Oncology (ASCO) meeting in Chicago. The open-label, U.S. trial is sponsored by Case Comprehensive Cancer Center...